Individualizing Care for Patients With Triple-Negative Breast Cancer
In this podcast episode from a live CCO Cancer Conversations webinar, Mark Pegram, MD, and Sara Tolaney, MD, MPH, provide expert perspectives on optimal treatment strategies for patients with triple-negative breast cancer (TNBC), with topics including:
- Current data and strategies for using PD-1/PD-L1 inhibitors in early-stage TNBC
- Clinical implications of PD-L1 status on therapeutic planning for patients with metastatic TNBC
- Current data and treatment strategies and the future of antibody–drug conjugates in the management of relapsed/refractory advanced TNBC
- Treatment implications of the presence of BRCA1/2 mutations and homologous recombination deficiency genes in advanced TNBC
- Role of PARP inhibitors in the treatment of TNBC
Presenters:
Mark Pegram, MD
Professor
Medical Oncology
Stanford University
Palo Alto, California
Sara Tolaney, MD, MPH
Associate Professor of Medicine
Division of Breast Oncology
Harvard Medical School
Chief, Division of Breast Oncology
Breast Oncology Program
Dana-Farber Cancer Institute
Boston, Massachusetts
Content based on an online CME/CE/CPE program supported by educational grants from Gilead Sciences, Inc.
Link to full program:
http://bit.ly/3iQzDz5
